Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey.

Acaster S, Gaugris S, Velikova G, Yong K, Lloyd AJ.

Support Care Cancer. 2013 Feb;21(2):599-607. doi: 10.1007/s00520-012-1548-y.

PMID:
22886429
2.

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, Davies FE.

Health Qual Life Outcomes. 2014 Mar 11;12:35. doi: 10.1186/1477-7525-12-35.

3.

Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis.

Kharroubi SA, Edlin R, Meads D, Browne C, Brown J, McCabe C.

Med Decis Making. 2015 Apr;35(3):351-60. doi: 10.1177/0272989X15575285.

PMID:
25784746
4.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
5.

Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument.

Espinoza-Zamora JR, Portilla-Espinosa CM, Labardini-Méndez JR, Cervera E, Niesvisky R, Oñate-Ocaña LF.

Ann Hematol. 2015 Jun;94(6):1017-24. doi: 10.1007/s00277-014-2290-y.

PMID:
25563595
6.

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T.

Haematologica. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121.

8.

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.

Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC.

Br J Haematol. 2008 Nov;143(4):511-9. doi: 10.1111/j.1365-2141.2008.07378.x.

PMID:
18986387
10.

Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.

Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D.

Value Health. 2009 Nov-Dec;12(8):1151-7. doi: 10.1111/j.1524-4733.2009.00569.x.

11.
12.
13.

Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument.

Wettergren L, Sprangers M, Björkholm M, Langius-Eklöf A.

Psychooncology. 2008 Apr;17(4):338-46.

PMID:
17614094
14.

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.

Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J; EORTC Quality of Life Group..

Eur J Cancer. 2007 Jul;43(11):1670-8.

PMID:
17574838
15.

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.

Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007.

PMID:
26149712
16.

Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma.

Kontodimopoulos N, Samartzis A, Papadopoulos AA, Niakas D.

ScientificWorldJournal. 2012;2012:842867. doi: 10.1100/2012/842867.

17.
18.

Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.

Kim SH, Jo MW, Kim HJ, Ahn JH.

Health Qual Life Outcomes. 2012 Dec 17;10:151. doi: 10.1186/1477-7525-10-151.

19.

Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.

Rowen D, Young T, Brazier J, Gaugris S.

Value Health. 2012 Dec;15(8):1059-68. doi: 10.1016/j.jval.2012.08.2201.

20.

Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.

Longworth L, Yang Y, Young T, Mulhern B, Hernández Alava M, Mukuria C, Rowen D, Tosh J, Tsuchiya A, Evans P, Devianee Keetharuth A, Brazier J.

Health Technol Assess. 2014 Feb;18(9):1-224. doi: 10.3310/hta18090. Review.

Items per page

Supplemental Content

Support Center